Li Tao, director of the Shandong Provincial Food and Drug Administration, and his entourage investigated drug safety supervision in Linyi

In order to fully implement the spirit of the 20th National Congress of the Communist Party of China and conscientiously implement the requirements of studying and implementing the theme education deployment of Xi Jinping's Thought on Socialism with Chinese Characteristics in the New Era, on July 27, Li Tao, secretary of the party group and director of the Shandong Provincial Drug Administration, and Lin Bingyong, member of the party group and deputy director of the bureau, led a team to Linyi pharmaceutical and medical device manufacturers to carry out on-site investigation activities. Relevant responsible comrades of Linyi Market Supervision Administration, the fifth branch of the Provincial Food and Drug Administration, Junan County and Yihe New District accompanied the investigation.

The research team successively went to Shandong Xin Gaoyi Medical Device Technology Co., Ltd., Gan & Lee Pharmaceutical Shandong Co., Ltd., Luoxin Pharmaceutical Group and Lunan Pharmaceutical Group to conduct field investigations, inspected the R & D, quality control, production and other departments of the enterprise, learned in detail about the product performance, technical level, process flow of the enterprise, listened to the report on the company's product research and development, variety registration, market prospects and development planning, etc., and interacted with the person in charge of the enterprise on the direction of industrial development and the problems to be solved. Constructive suggestions were put forward on site to ensure drug safety and accelerate innovation and development.

During the investigation, Li Tao and his entourage inquired in detail about the difficulties encountered by enterprises in terms of production licensing, product registration, variety transfer, etc., and answered them one by one with the accompanying personnel. Li Tao pointed out that enterprises should increase product research and development and market promotion, improve the quality control system, cultivate and build a new engine of high-quality and sustainable development of enterprises, and inject new vitality into the economy, society and people's livelihood. The Provincial Food and Drug Administration will take the theme education as an opportunity to widely collect opinions and suggestions from enterprises, improve service quality in a targeted manner, optimize the review and approval process, strengthen the all-round guidance of "front-end", "bottom-up" and "face-to-face", and strive to create a first-class business environment.

Li Tao also accompanied Shen Chuanyong, director of the National Adverse Drug Reaction Monitoring Center, to inspect the monitoring of adverse drug reactions of drug marketing authorization holders and pharmaceutical manufacturers. Li Tao emphasized that drug safety is the lifeline of enterprises, enterprises bear the main responsibility of drugs, must always put quality and safety in the first place, strengthen source, process, personnel management, and continuously improve the level of quality control. It is necessary to actively collect, track and analyze information on suspected adverse drug reactions, promptly adopt risk control measures for drugs with identified risks, strengthen the management of the whole life cycle of drugs, and ensure the safety of marketed drugs.

During the investigation, Li Tao made arrangements for promoting the consolidation and improvement of drug safety and implementing the territorial responsibility for drug safety. He stressed that drug regulatory departments at all levels should earnestly assume the responsibility of drug safety supervision, so as to ensure that they have a responsibility to defend the land and fulfill their responsibilities, and guard the bottom line of not occurring regional and systemic drug safety risks. Efforts should be made to build a drug safety governance pattern in which departments supervise according to law, industry integrity and self-discipline, all parties in society collaborate, and the public actively participates, continuously enhance the people's sense of gain, happiness, and security, and create a stable and good drug safety environment for the province to promote high-quality development.

Shandong Zhushi Pharmaceutical Group Co., Ltd., founded in 2003, has more than 5000 registered employees. After years of development, it has developed into a diversified industrial cluster integrating medical devices, polymers, cosmetics, health food, daily necessities and biological reagent production, enterprise management consulting and training, real estate economy, pharmaceutical transportation, pharmaceutical printing, etc.

Adhering to the concept of life, health and happiness, the Group provides you with full chain health services.

HOT

NEW